1.Analysis of risk factors associated with endoscopic retrograde cholangiopancreatography for patients with liver cirrhosis: a multicenter, retrospective, clinical study.
Jielin LI ; Jiexuan HU ; Peng LI ; Yongdong WU ; Yongjun WANG ; Ming JI ; Haiyang HUA ; Wenbin RAN ; Yanglin PAN ; Shutian ZHANG
Chinese Medical Journal 2022;135(19):2319-2325
		                        		
		                        			BACKGROUND:
		                        			Endoscopic retrograde cholangiopancreatography (ERCP) is the endoscopic modality of choice for the treatment of biliary and pancreatic diseases. However, patients with cirrhosis, particularly those with decompensated cirrhosis, are believed to be at increased risk for complications associated with ERCP. There is a paucity of literature describing the outcomes of ERCP for patients with cirrhosis. This study aimed to investigate the outcomes of ERCP for cirrhosis patients, especially adverse events, and evaluated its safety and efficacy.
		                        		
		                        			METHODS:
		                        			We performed a multicenter, retrospective study of all patients at Beijing Friendship Hospital affiliated to Capital Medical University, Xijing Hospital affiliated to Air Force Military Medical University, Beijing Youan Hospital affiliated to Capital Medical University, and the Fifth Medical Center of the People's Liberation Army General Hospital from June 2003 to August 2019. The adverse events of inpatient ERCP for patients with ( n  = 182) and without liver cirrhosis (controls; n  = 385) were compared.
		                        		
		                        			RESULTS:
		                        			A total of 567 patients underwent ERCP between January 2003 and December 2019 were enrolled in this study. Compared to patients without cirrhosis, patients with cirrhosis were at higher risk for postoperative complications (odds ratio [OR], 4.172; 95% confidence interval [CI], 1.232-7.031; P  < 0.001) such as postoperative pancreatitis (OR, 2.026; 95% CI, 1.002-4.378; P  = 0.001) and cholangitis (OR, 3.903; 95% CI, 1.001-10.038; P  = 0.036). The main indications for ERCP for patients with cirrhosis in this study included choledocholithiasis (101 cases; 55.5%), benign bile duct strictures (46 cases; 25.3%), and malignant bile duct strictures (28 cases; 15.4%). Among them, 23 patients (12.6%) underwent balloon dilation and 79 patients (43.4%) underwent sphincterotomy. Of the patients with cirrhosis, delayed bleeding occurred in ten patients (5.5%), postoperative pancreatitis occurred in 80 patients (44.0%), and postoperative cholangitis occurred in 25 patients (13.7%). An additional multivariate analysis showed that the total bilirubin (TBIL) level (OR, 4.58; 95% CI, 2.37-6.70) and Child-Pugh score of C (OR, 3.11; 95% CI, 1.04-5.37) were risk factors for postoperative complications in patients with cirrhosis.
		                        		
		                        			CONCLUSIONS
		                        			Compared with the general population of patients undergoing ERCP, patients with cirrhosis were more prone to postoperative pancreatitis and cholangitis. TBIL levels and Child-Pugh scores were risk factors for postoperative complications in patients with cirrhosis.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Cholangiopancreatography, Endoscopic Retrograde/adverse effects*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Constriction, Pathologic
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Liver Cirrhosis/complications*
		                        			;
		                        		
		                        			Pancreatitis/etiology*
		                        			;
		                        		
		                        			Postoperative Complications/epidemiology*
		                        			;
		                        		
		                        			Cholangitis
		                        			
		                        		
		                        	
2.Course of disease and related epidemiological parameters of COVID-19: a prospective study based on contact tracing cohort.
Yan ZHOU ; Wen Jia LIANG ; Zi Hui CHEN ; Tao LIU ; Tie SONG ; Shao Wei CHEN ; Ping WANG ; Jia Ling LI ; Yun Hua LAN ; Ming Ji CHENG ; Jin Xu HUANG ; Ji Wei NIU ; Jian Peng XIAO ; Jian Xiong HU ; Li Feng LIN ; Qiong HUANG ; Ai Ping DENG ; Xiao Hua TAN ; Min KANG ; Gui Min CHEN ; Mo Ran DONG ; Hao Jie ZHONG ; Wen Jun MA
Chinese Journal of Preventive Medicine 2022;56(4):474-478
		                        		
		                        			
		                        			Objective: To analyze the course of disease and epidemiological parameters of COVID-19 and provide evidence for making prevention and control strategies. Methods: To display the distribution of course of disease of the infectors who had close contacts with COVID-19 cases from January 1 to March 15, 2020 in Guangdong Provincial, the models of Lognormal, Weibull and gamma distribution were applied. A descriptive analysis was conducted on the basic characteristics and epidemiological parameters of course of disease. Results: In total, 515 of 11 580 close contacts were infected, with an attack rate about 4.4%, including 449 confirmed cases and 66 asymptomatic cases. Lognormal distribution was fitting best for latent period, incubation period, pre-symptomatic infection period of confirmed cases and infection period of asymptomatic cases; Gamma distribution was fitting best for infectious period and clinical symptom period of confirmed cases; Weibull distribution was fitting best for latent period of asymptomatic cases. The latent period, incubation period, pre-symptomatic infection period, infectious period and clinical symptoms period of confirmed cases were 4.50 (95%CI:3.86-5.13) days, 5.12 (95%CI:4.63-5.62) days, 0.87 (95%CI:0.67-1.07) days, 11.89 (95%CI:9.81-13.98) days and 22.00 (95%CI:21.24-22.77) days, respectively. The latent period and infectious period of asymptomatic cases were 8.88 (95%CI:6.89-10.86) days and 6.18 (95%CI:1.89-10.47) days, respectively. Conclusion: The estimated course of COVID-19 and related epidemiological parameters are similar to the existing data.
		                        		
		                        		
		                        		
		                        			COVID-19
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Contact Tracing
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Prospective Studies
		                        			
		                        		
		                        	
3. doxorubicin induces chronic heart failure in rats by regulating mitochondrial dynamics via drp1/fundc1 pathway
Ran XIA ; Guo-Qi ZHU ; Bing GAO ; Meng ZHU ; Ling-Ji LI ; Heng WANG ; Zhu WANG ; Jing WANG ; Xiao-Hua DAI
Chinese Pharmacological Bulletin 2022;38(11):1661-1666
		                        		
		                        			
		                        			 Aim To investigate the damage degree of doxorubicin hydrochloride( DOX )on cardiac function in rats, and to explore its possible mechanism. Methods Experiment 1: SD rats( n=48 )were randomly divided into control group( normal saline ), DOX 1 group( DOX cumulative dose 12 mg·kg-1 ;intraperitoneal injection ), DOX 2 group( 15 mg·kg-1 ;)and DOX 3 group( 18 mg·kg-1 ;). Cardiac structure and cardiac function were detected by echocardiography. B-type natriuretic peptide( BNP )was detected by ELISA. The morphological changes of myocardium were observed by Hematoxylin-eosin( HE )staining. The optimal dose group( DOX 2 group )was selected comprehensively. Experiment 2: SD rats( n=36 )were randomly divided into control group( normal saline ), DOX 2 group(15 mg·kg-1)and DOX 2+Mdivi-1 group( 15 mg·kg-1+daily abdominal injection of Mdivi-1(1 mg ·kg-1 ;)). Western blot was used to detect the protein expression of myocardial mitochondrial dynamics. Results Compared with the control group, hearts in DOX groups were enlarged and the heart function was reduced. Under the microscope, hypertrophy of cardiac cells and loose arrangement of cardiac fibers were observed in DOX group, and the higher the cumulative dose of DOX in rats, the more severe the degree of heart failure and the higher the mortality rate of rats. Compared with control group, the expression of mitochondrial dynamin-related protein 1( DRP1 )and related signaling pathway protein FUN14 domain containing 1( FUNDC1 )in DOX 2 group increased. The expression of optic atrophy 1( OPA1 )decreased, the expression of FUNDC1 and DRP1 protein decreased, and the expression of OPA1 protein was enhanced after the use of mitochondrial dynamics inhibitor(Mdivi-1). Conclusions DOX can cause chronic heart failure, and the mechanism may be related to DRP1/FUNDC1 mediated mitochondrial fission and fusion. 
		                        		
		                        		
		                        		
		                        	
4.Efficacy of Getong Tongluo Capsule () for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial.
Qian-Yu ZHAO ; Rong-Hua TANG ; Guo-Xiong LU ; Xu-Zheng CAO ; Lu-Ran LIU ; Ji-Hua ZHANG ; Jin-Tao ZHANG ; Bin XU ; Hong-Tao WEI ; Miao YANG ; Ling WEI ; Mei ZHANG ; Wen-Zong ZHU ; Hong WANG ; Hong-Lin LI ; Li-Ping MA ; Chi ZHONG ; Yan-Jie GAO ; Na ZHANG ; Shan REN ; Lu CHEN ; Yun-Hai LIU ; Zhi-Gang CHEN
Chinese journal of integrative medicine 2021;27(4):252-258
		                        		
		                        			OBJECTIVE:
		                        			To evaluate whether the efficacy of Getong Tongluo Capsule (, GTC, consisted of total flavone of Radix Puerariae) on improving patients' quality of life and lowering blood pressure are superior to the extract of Ginkgo biloba (EGB) for patients with convalescent-phase ischemic stroke and primary hypertension.
		                        		
		                        			METHODS:
		                        			This randomized, positive-drug- and placebo-controlled, double-blind trial was conducted from September 2015 to October 2017. Totally 477 eligible patients from 18 hospitals in China were randomly assigned in a 2:1:1 ratio to the following interventions, twice a day for 12 weeks: (1) GTC 250 mg plus EGB-matching placebo 40 mg (237 cases, GTC group), (2) EGB 40 mg plus GTC-matching placebo 250 mg (120 cases, EGB group) or (3) GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg (120 cases, placebo group). Moreover, all patients were orally administered aspirin enteric-coated tablets 100 mg, once a day for 12 weeks. The primary outcome was the Barthel Index (BI). The secondary outcomes included the control rate of blood pressure and National Institutes of Health Stroke Scale (NIHSS) scores. The incidence and severity of adverse events (AEs) were calculated and assessed.
		                        		
		                        			RESULTS:
		                        			The BI relative independence rates, the clinical recovery rates of NIHSS, and the total effective rates of NIHSS in the GTC and EGB groups were significantly higher than the placebo group at 12 weeks after treatment (P<0.05), and no statistical significance was found between the GTC and EGB groups (P>0.05). The control rate of blood pressure in the GTC group was significantly higher than the EGB and placebo groups at 12, 18 and 24 weeks after treatment (P<0.01). There were no statistically significant differences in the incidences of AEs, adverse drug reactions, or serious AEs among the 3 groups (P>0.05).
		                        		
		                        			CONCLUSION
		                        			GTC exhibited significant efficacy in improving patients' quality of life as well as neurological function and controlling hypertension. (Registration No. ChiCTR1800016667).
		                        		
		                        		
		                        		
		                        	
5.Inactivation of Poliovirus by Ozone and the Impact of Ozone on the Viral Genome.
Han Ji JIANG ; Na CHEN ; Zhi Qiang SHEN ; Jing YIN ; Zhi Gang QIU ; Jing MIAO ; Zhong Wei YANG ; Dan Yang SHI ; Hua Ran WANG ; Xin Wei WANG ; Jun Wen LI ; Dong YANG ; Min JIN
Biomedical and Environmental Sciences 2019;32(5):324-333
		                        		
		                        			OBJECTIVE:
		                        			To investigate the mechanisms underlying ozone-induced inactivation of poliovirus type 1 (PV1).
		                        		
		                        			METHODS:
		                        			We used cell culture, long-overlapping RT-PCR, and spot hybridization assays to verify and accurately locate the sites of action of ozone that cause PV1 inactivation. We also employed recombinant viral genome RNA infection models to confirm our observations.
		                        		
		                        			RESULTS:
		                        			Our results indicated that ozone inactivated PV1 primarily by disrupting the 5'-non-coding region (5'-NCR) of the PV1 genome. Further study revealed that ozone specifically damaged the 80-124 nucleotide (nt) region in the 5'-NCR. Recombinant viral genome RNA infection models confirmed that PV1 lacking this region was non-infectious.
		                        		
		                        			CONCLUSION
		                        			In this study, we not only elucidated the mechanisms by which ozone induces PV1 inactivation but also determined that the 80-124 nt region in the 5'-NCR is targeted by ozone to achieve this inactivation.
		                        		
		                        		
		                        		
		                        			5' Untranslated Regions
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Cercopithecus aethiops
		                        			;
		                        		
		                        			Genome, Viral
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Oxidants, Photochemical
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Ozone
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Poliovirus
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Vero Cells
		                        			;
		                        		
		                        			Virus Inactivation
		                        			
		                        		
		                        	
6.TNF-α/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms.
Xiuhua MIAO ; Ya HUANG ; Teng-Teng LIU ; Ran GUO ; Bing WANG ; Xue-Long WANG ; Li-Hua CHEN ; Yan ZHOU ; Ru-Rong JI ; Tong LIU
Neuroscience Bulletin 2018;34(1):42-53
		                        		
		                        			
		                        			Increasing evidence suggests that cytokines and chemokines play crucial roles in chronic itch. In the present study, we evaluated the roles of tumor necrosis factor-alpha (TNF-α) and its receptors TNF receptor subtype-1 (TNFR1) and TNFR2 in acute and chronic itch in mice. Compared to wild-type (WT) mice, TNFR1-knockout (TNFR1-KO) and TNFR1/R2 double-KO (DKO), but not TNFR2-KO mice, exhibited reduced acute itch induced by compound 48/80 and chloroquine (CQ). Application of the TNF-synthesis inhibitor thalidomide and the TNF-α antagonist etanercept dose-dependently suppressed acute itch. Intradermal injection of TNF-α was not sufficient to evoke scratching, but potentiated itch induced by compound 48/80, but not CQ. In addition, compound 48/80 induced TNF-α mRNA expression in the skin, while CQ induced its expression in the dorsal root ganglia (DRG) and spinal cord. Furthermore, chronic itch induced by dry skin was reduced by administration of thalidomide and etanercept and in TNFR1/R2 DKO mice. Dry skin induced TNF-α expression in the skin, DRG, and spinal cord and TNFR1 expression only in the spinal cord. Thus, our findings suggest that TNF-α/TNFR1 signaling is required for the full expression of acute and chronic itch via peripheral and central mechanisms, and targeting TNFR1 may be beneficial for chronic itch treatment.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Chloroquine
		                        			;
		                        		
		                        			toxicity
		                        			;
		                        		
		                        			Disease Models, Animal
		                        			;
		                        		
		                        			Dose-Response Relationship, Drug
		                        			;
		                        		
		                        			Etanercept
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Ganglia, Spinal
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Inbred C57BL
		                        			;
		                        		
		                        			Mice, Transgenic
		                        			;
		                        		
		                        			Pruritus
		                        			;
		                        		
		                        			chemically induced
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			RNA, Messenger
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Receptors, Tumor Necrosis Factor, Type I
		                        			;
		                        		
		                        			deficiency
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Receptors, Tumor Necrosis Factor, Type II
		                        			;
		                        		
		                        			deficiency
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Signal Transduction
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Skin
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Spinal Cord
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Thalidomide
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Time Factors
		                        			;
		                        		
		                        			Tumor Necrosis Factor-alpha
		                        			;
		                        		
		                        			adverse effects
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			p-Methoxy-N-methylphenethylamine
		                        			;
		                        		
		                        			toxicity
		                        			
		                        		
		                        	
7.Preparation and preliminary evaluation of chitosan composite KGF-2 mutant thermal sensitive dressing
Wen-Liang FU ; Hao-Ran JING ; Min-Ji ZOU ; Hui-Hua CHEN ; Wen-Rong XIA ; Wei-Wei XING ; Li-Jun ZHOU ; Dong-Gang XU
Military Medical Sciences 2018;42(1):13-16
		                        		
		                        			
		                        			Objective To develop chitosan composite keratinocyte growth factor-2 mutant(KGF-2M)temperature-sen-sitive dressing and evaluate its physicochemical properties and dynamic release rule were used.Methods Chitosan, chi-tosan quaternary ammonium salt,β-glycerophosphate and other adjuvant materials to configure different formulations which were compounded with KGF-2M in order to develop temperature-sensitive dressing.Gelling time, temperature,the release rate of KGF-2M and other indicators were measured to analyze the physical and chemical properties of the temperature -sen-sitive dressing.Results Chitosan-KGF-2M composite dressing with temperature-sensitive properties was obtained by opti-mizing the formulation components of chitosan and related adjuvant materials.When the liquid dressing was above 35℃,it could be converted from liquid to solid gelatin within 10 minutes.The compound KGF-2M released from the gel was more than 98%at 4 h,and its bioactivity remained stable.Conclusion The thermo-sensitive gel has the characteristics of good conformability,moisturizing(moisture),isolation,wound healing,and a controlled release effect,which has great potential in wartime for wound repair.
		                        		
		                        		
		                        		
		                        	
8.A Computerized Evaluation of Sensory Memory and Short-term Memory Impairment After Rapid Ascent to 4280 m.
Qing Hai SHI ; Di GE ; Wei ZHAO ; Xue MA ; Ke Yan HU ; Yao LU ; Zheng Xiang LIU ; Ji Hua RAN ; Xiao Ling LI ; Yu ZHOU ; Jian Feng FU
Biomedical and Environmental Sciences 2016;29(6):457-460
		                        		
		                        			
		                        			To evaluate the effect of acute high-altitude exposure on sensory and short-term memory using interactive software, we transported 30 volunteers in a sport utility vehicle to a 4280 m plateau within 3 h. We measured their memory performance on the plain (initial arrival) and 3 h after arrival on the plateau using six measures. Memory performance was significantly poorer on the plateau by four of the six measures. Furthermore, memory performance was significantly poorer in the acute mountain sickness (AMS) group than in the non-AMS group by five of the six measures. These findings indicate that rapid ascent to 4280 m and remaining at this altitude for 3 h resulted in decreased sensory and short-term memory, particularly among participants who developed AMS.
		                        		
		                        		
		                        		
		                        			Acute Disease
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Altitude
		                        			;
		                        		
		                        			Altitude Sickness
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			etiology
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Memory Disorders
		                        			;
		                        		
		                        			epidemiology
		                        			;
		                        		
		                        			etiology
		                        			;
		                        		
		                        			Memory, Short-Term
		                        			;
		                        		
		                        			Time Factors
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
9.Effects of Calcium Sulfate Combined with Platelet-rich Plasma on Restoration of Long Bone Defect in Rabbits.
Hua CHEN ; Xin-Ran JI ; Qun ZHANG ; Xue-Zhong TIAN ; Bo-Xun ZHANG ; Pei-Fu TANG
Chinese Medical Journal 2016;129(5):557-561
BACKGROUNDThe treatment for long bone defects has been a hot topic in the field of regenerative medicine. This study aimed to evaluate the therapeutic effects of calcium sulfate (CS) combined with platelet-rich plasma (PRP) on long bone defect restoration.
METHODSA radial bone defect model was constructed through an osteotomy using New Zealand rabbits. The rabbits were randomly divided into four groups (n = 10 in each group): a CS combined with PRP (CS-PRP) group, a CS group, a PRP group, and a positive (recombinant human bone morphogenetic protein-2) control group. PRP was prepared from autologous blood using a two-step centrifugation process. CS-PRP was obtained by mixing hemihydrate CS with PRP. Radiographs and histologic micrographs were generated. The percentage of bone regenerated bone area in each rabbit was calculated at 10 weeks. One-way analysis of variance was performed in this study.
RESULTSThe radiographs and histologic micrographs showed bone restoration in the CS-PRP and positive control groups, while nonunion was observed in the CS and PRP groups. The percentages of bone regenerated bone area in the CS-PRP (84.60 ± 2.87%) and positive control (52.21 ± 4.53%) groups were significantly greater than those in the CS group (12.34 ± 2.17%) and PRP group (16.52 ± 4.22%) (P < 0.001). In addition, the bone strength of CS-PRP group (43.10 ± 4.10%) was significantly greater than that of the CS group (20.10 ± 3.70%) or PRP group (25.10 ± 2.10%) (P < 0.001).
CONCLUSIONCS-PRP functions as an effective treatment for long bone defects through stimulating bone regeneration and enhancing new bone strength.
Animals ; Bone Regeneration ; drug effects ; Calcium Sulfate ; pharmacology ; Male ; Platelet-Rich Plasma ; Rabbits
10.Hydrogen Therapy Reduces Oxidative Stress-associated Risks Following Acute and Chronic Exposure to High-altitude Environment.
Qing Hai SHI ; Wei WEI ; Ji Hua RAN ; Si Yuan WANG ; Zheng Xiang LIU ; Di GE ; Ping CHEN ; Jian Feng FU
Biomedical and Environmental Sciences 2015;28(3):239-241
		                        		
		                        			
		                        			Low pressure, low oxygen concentration, and intense ultraviolet (UV) radiation in high-altitude environments, can cause oxidative stress which can trigger mountain sickness. A recent study demonstrated that hydrogen gas with a good permeability in biological membranes can treat various disorders by exerting its selective anti-oxidation and anti-inflammatory effects, indicating that hydrogen therapy plays a role in scavenging free radicals and in balancing oxidation and anti-oxidation systems of cells. Therefore, we hypothesize that inhaling low-dose hydrogen or drinking hydrogen-saturated water is a novel and simple method to prevent and treat oxidative stress injury caused by low pressure, low oxygen concentration and intense UV radiation in plateaus, thus reducing the risk of mountain sickness.
		                        		
		                        		
		                        		
		                        			Altitude
		                        			;
		                        		
		                        			Environmental Exposure
		                        			;
		                        		
		                        			Free Radical Scavengers
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hydrogen
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Oxidative Stress
		                        			;
		                        		
		                        			Oxygen
		                        			;
		                        		
		                        			analysis
		                        			;
		                        		
		                        			Ultraviolet Rays
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail